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SynthesisAbstract Keeping in view the immense biological importance of ﬂuoroquinolones and amin-
obenzothiazoles as antimicrobials and in search for better antibacterial agents, design and synthesis
of new ﬂuoroquinolone derivatives having substituted piperazine rings at the C-7 position are
described in the present communication. The synthesized compounds were characterized by suitable
spectroscopic methods. Most of the new compounds (4a–l) demonstrated high in vitro antibacterial
activity with some compounds exhibiting more potent activities against Gram-positive organisms
than those of ciproﬂoxacin, norﬂoxacin and gatiﬂoxacin. The results of the present study reveal that
the compounds have signiﬁcant antibacterial potential and are suitable candidates for further explo-
ration.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Fluoroquinolones have been the landmark discovery in the
treatment of bacterial infections (Srivastava et al., 2007). Dur-
ing recent years much attention has been devoted to the syn-
thesis of new ﬂuoroquinolones for their antibacterial activity
(Jazayeri et al., 2009). Despite a large number of approved ﬂu-
oroquinolones for treatment of various infections, there have
been unabated efforts for the discovery of ﬂuoroquinolones
with speciﬁc properties, such as desired pharmacokinetic pro-
ﬁle, therapeutic index and more importantly to overcome the
problems of growing bacterial resistance (Srivastava et al.,
Figure 2 Structure of norﬂoxacin and ciproﬂoxacin. 1, Norﬂox-
acin R = ethyl 2, Ciproﬂoxacin R = cyclopropyl.
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tance especially to Staphylococci and Enterococci. Some of the
side effects, such as central nervous system effects, phototoxic-
ity, tendonitis, hypoglycemia and serious cardiac dysarryth-
mias of quinolone antibacterials are unacceptable, for
example, grepaﬂoxacin was withdrawn from market due to in-
creased cases of heart problems in clinical ﬁndings. Similarly
trovaﬂoxacin was removed from the market due to liver toxic-
ity (Graul and Rabasseda, 1999). Hence, there is an utmost
need to develop newer ﬂuoroquinolone analogs with enhanced
potency and broad spectrum of activity.
Most of the quinolone antibacterial research has been fo-
cused on the functionality at C-7 position since the introduc-
tion of norﬂoxacin 1 and ciproﬂoxacin 2 (Figs. 1 and 2)
(Foroumadi et al., 2005, 2006). Moreover, C-7 substituent is
the most adaptable site for chemical intervention and is an
area that determines the potency and target preferences. This
area also controls the pharmacokinetic properties of the drug
with basic nitrogen. A ﬁve or six membered ring is the most
commonly employed substitution at position C-7, for example,
gemiﬂoxacin and trovaﬂoxacin having aminopyrrolidine sub-
stituent at C-7 (Sharma et al., 2009, 2010; Domagala et al.,
1988). Piperazine substituents at C-7 position have resulted
in a wide range of clinically useful ﬂuoroquinolone antibacte-
rial agents namely norﬂoxacin, ciproﬂoxacin, perﬂoxacin,
peﬂoxacin, oﬂoxacin, amiﬂoxacin, ﬂeroxacin, lomeﬂoxacin,
sparﬂoxacin, diﬂoxacin, enoxacin, enroﬂoxacin, levoﬂoxacin,
marboﬂoxacin and orbiﬂoxacin. Fluoroquinolones with 7-pip-
erazinyl moiety have been reported to possess potent antibac-
terial activity (Foroumadi et al., 2005).
Mechanism of action and structure activity relationship
studies of quinolones reveals that the site near the C-7 substi-
tuent is regarded as the drug enzyme interaction domain. In
addition, it is also reported that the cell permeability is domi-
nantly controlled by C-7 substituents. These facts motivated
our concerns to develop some C-7 substituted analogs of quin-
olone. The piperazine moiety of ﬂuoroquinolones possesses en-
ough structural ﬂexibility to allow product optimization
(Foroumadi et al., 2006). Thus, we anticipated that safer and
superior antibacterial compounds could be developed by
attaching appropriate moiety through N-atom of the substitu-
ents at C-7 position. Hence, in the present communication we
report the synthesis, characterization and antibacterial activity
of some N-substituted piperazinyl quinolones by introducing
speciﬁc substituents in the piperazine unit of 7-piperazinyl
quinolones.
Small ring heterocycles bearing nitrogen, sulfur and oxygen
have been under investigation for long time because of their
important medicinal activities (Kumar et al., 2011). Moreover,












Figure 1 Quinolone core with main substitution sites.cytotoxic, antibacterial, fungicidal, analgesic, antiinﬂamma-
tory, antioxidant activities and quinolone derivatives are also
found to possess antibacterial, antimycobacterial, antimalarial,
antioxidant, analgesic and antiviral activities (Chu et al., 1985;
Senthilkumar et al., 2009; Jayashree et al., 2009; El-Gazzar
et al., 2009; Dinakaran et al., 2008; Winter et al., 2008;
German et al., 2008; Sharma and Jain, 2008). Thus keeping
in view these facts, the present study was aimed to achieve bet-
ter antimicrobial proﬁle at lower concentrations, by preparing




All the chemicals and solvents used in this study were labora-
tory grade and procured from E. Merck (Germany), S. D. Fine
Chemicals (India). Melting points were determined on a
Labindia MR-VIS visual melting point apparatus and are
uncorrected. The thin layer chromatography (TLC) plates
(Silica Gel G) were used to conﬁrm the purity of commercial
reagents used, compounds synthesized and to monitor the
reactions as well. Absorbance values against wavelength were
taken on a Systronic double beam UV-166 spectrophotometer.
The IR spectra were obtained on a Perkin Elmer IR spectro-
photometer (KBr pellet). 1H NMR spectra were recorded
using Bruker 400 spectrometer and chemical shifts are
expressed as d (ppm) using tetramethylsilane as an internal
standard in DMSO-d6. Mass spectra of some selected com-
pounds were obtained using a micromass-Q-Tof-micro
spectrometer.
2.2. Chemistry
2.2.1. General procedure for synthesis of 2-amino-6-substituted
benzothiazole (2a–e)
The 2-amino-6-substituted benzothiazoles (2a–e) were pre-
pared by mixing p-substituted aniline (0.05 mol) (1a–e) and
potassium thiocyanate (0.2 mol) in 90 ml of 96% acetic acid.
To this was added drop wise, with stirring, a solution of bro-
mine (0.05 mol) in glacial acetic acid (37.5 ml) and temperature
was maintained below 35C. After all the bromine solution
was added, the mixture was stirred for another 10 h at room
temperature and was ﬁltered, the residue so obtained was
washed with water. The combined ﬁltrate and washings were
neutralized with ammonium hydroxide solution. The precipi-
tate thus obtained was collected and dried. Further puriﬁca-
tion was carried out by crystallization from benzene.
Adopting the above procedure, ﬁve different 2-amino-6-substi-
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of the benzothiazoles was checked by TLC.
2.2.2. General procedure for synthesis of ﬂuoroquinolone
derivatives (4a–l)
For synthesis of target ﬂuoroquinolone derivatives (4a–l), a
mixture of 2-amino-6-substituted benzothiazole (0.05 mmol)
(2a–e), respective ﬂuoroquinolone (0.05 mmol) (3a–c) and for-
malin (0.05 mmol) in acetic acid (10 ml), was reﬂuxed for 10 h.
After complete consumption of ﬂuoroquinolone (monitored
by thin layer chromatography), ammonia solution was added
drop wise till neutralization and the precipitate was ﬁltered
and washed with water to yield the crude product. The purity
of ﬁnal compounds was ascertained by thin layer chromatog-
raphy. By adopting the captioned procedure, twelve com-
pounds (4a–l) were synthesized.
2.2.2.1. 1-Ethyl-6-ﬂuoro-7-(4-(N-(6-methoxy-1,3-benzothiazol-
2-yl)aminomethyl)piperazin-1-yl)-1,4-dihydro-4-oxo-quinoline-
3-carboxylic acid (4a). Mp 190–193 C (63% yield). 1H NMR
(DMSO-d6): d/ppm = 1.37 (3H, J= 6.6, t, CH3 ethyl), 2.47
(2H, J= 6.6, q, CH2 ethyl), 3.12–3.57 (8H, m, piperazine),
3.76 (3H, s, OCH3 benzothiazole), 5.68 (2H, s, CH2 methylene
bridge), 5.06 (1H, s, NH), 6.87–7.90 {5H, m, aromatic proton
(H5, H8-quinolone and H40, H50, H70-benzothiazole)}, 8.91
(1H, s, H2-quinolone), 15.12 (1H, s, COOH); IR (KBr):
cm1 = 1585 (C‚C), 1710 (C‚O), 1257 (C–O), 1057 (C–N),
2939–2831 (C–H), 3302 (COOH); MS: m/z= 511.6 (M+).
2.2.2.2. 1-Ethyl-6-ﬂuoro-7-(4-(N-(6-nitro-1,3-benzothiazol-2-
yl)aminomethyl)piperazin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-
carboxylic acid (4b). Mp 235–237 C (66% yield). 1H NMR
(DMSO-d6): d/ppm = 1.39 (3H, J= 6.9, t, CH3 ethyl), 2.29
(2H, J= 6.9, q, CH2 ethyl), 3.17–3.62 (8H, m, piperazine),
5.32 (2H, s, CH2 methylene bridge), 4.87 (1H, s, NH), 6.98–
7.94 {5H, m, aromatic proton (H5, H8-quinolone and H40,
H50, H70-benzothiazole)}, 8.68 (1H, s, H2-quinolone), 15.01
(1H, s, COOH); IR (KBr): cm1 = 1574 (C‚C), 1718
(C‚O), 1296 (C–O), 1126 (C–N), 3101-2854 (C–H), 3317
(COOH); MS: m/z= 526.5 (M+).
2.2.2.3. 1-Ethyl-6-ﬂuoro-7-(4-(N-(6-methyl-1,3-benzothiazol-2-
yl)aminomethyl)piperazin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-
carboxylic acid (4c). Mp 211–213 C (68% yield). 1H NMR
(DMSO-d6): d/ppm = 1.35 (3H, J= 5.7, t, CH3 ethyl), 2.31
(2H, J= 5.7, q, CH2 ethyl), 3.01–3.64 (8H, m, piperazine),
2.46 (3H, s, CH3 benzothiazole), 5.71 (2H, s, CH2 methylene
bridge), 5.10 (1H, s, NH), 6.98–7.89 {5H, m, aromatic proton
(H5, H8-quinolone and H40, H50, H70-benzothiazole)}, 8.92
(1H, s, H2 quinolone), 14.94 (1H, s, COOH); IR (KBr):
cm1 = 1585 (C‚C), 1706 (C‚O), 1257 (C–O), 1103 (C–N),
3024-2862 (C–H), 3294 (COOH); MS: m/z= 495.6 (M+).
2.2.2.4. 1-Ethyl-6-ﬂuoro-7-(4-(N-(6-ﬂuoro-1,3-benzothiazol-2-
yl)aminomethyl)piperazin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-
carboxylic acid (4d). Mp 222–225 C (70% yield). 1H NMR
(DMSO-d6): d/ppm = 1.38 (3H, J= 6.3, t, CH3 ethyl), 1.89
(2H, J= 6.3, q, CH2 ethyl), 3.03–3.61 (8H, m, piperazine),
5.75 (2H, s, CH2 methylene bridge), 5.12 (1H, s, NH), 7.17–
7.78 {5H, m, aromatic proton (H5, H8-quinolone and H40,
H50, H70-benzothiazole)}, 8.90 (1H, s, H2-quinolone), 14.88




carboxylic acid (4e). Mp 198–200 C (59% yield). 1H NMR
(DMSO-d6): d/ppm = 1.29 (3H, J= 5.4, t, CH3 ethyl), 1.96
(2H, J= 5.4, q, CH2 ethyl), 2.94–3.59 (8H, m, piperazine),
5.62 (2H, s, CH2 methylene bridge), 5.07 (1H, s, NH), 7.09–
8.20 {5H, m, aromatic proton (H5, H8-quinolone and H40,
H50, H70-benzothiazole)}, 9.03 (1H, s, H2-quinolone), 14.98
(1H, s, COOH); IR (KBr): cm1 = 1585 (C‚C), 1682
(C‚O), 1273 (C–O), 1080 (C–N), 3063 (C–H), 3271 (COOH).
2.2.2.6. 1-Cyclopropyl-6-ﬂuoro-7-(4-(N-(6-methoxy-1,3-ben-
zothiazol-2-yl)amino methyl)piperazin-1-yl)-1,4-dihydro-4-
oxo-quinoline-3-carboxylic acid (4f). Mp 267–270 C (62%
yield). 1H NMR (DMSO-d6): d/ppm = 1.17 (4H, J= 7.2, d,
CH2–CH2– cyclopropyl), 3.02–3.11 (1H, m, CH cyclopropyl),
3.37–3.80 (8H, m, piperazine), 3.89 (3H, s, OCH3 benzothia-
zole), 5.71 (2H, s, CH2 methylene bridge), 5.10 (1H, s, NH),
6.89–7.49 {5H, m, aromatic proton (H5, H8-quinolone and
H40, H50, H70-benzothiazole)}, 8.68 (1H, s, H2-quinolone),
14.89 (1H, s, COOH); IR (KBr): cm1 = 1585 (C‚C), 1710
(C‚O), 1257 (C–O), 1057 (C–N), 2939–2831 (C–H), 3302
(COOH); MS: m/z= 523.6 (M+).
2.2.2.7. 1-Cyclopropyl-6-ﬂuoro-7-(4-(N-(6-nitro-1,3-ben-
zothiazol-2-yl)amino methyl)piperazin-1-yl)-1,4-dihydro-4-
oxo-quinoline-3-carboxylic acid (4g). Mp 242–245 C (63%
yield). 1H NMR (DMSO-d6): d/ppm = 1.27 (4H, J= 6.0, d,
CH2–CH2– cyclopropyl), 3.07–3.15 (1H, m, CH cyclopropyl),
3.30–3.73 (8H, m, piperazine), 5.32 (2H, s, CH2 methylene
bridge), 5.00 (1H, s, NH), 7.21–7.87 {5H, m, aromatic proton
(H5, H8-quinolone and H40, H50, H70-benzothiazole)}, 8.79 (1H,
s, H2-quinolone), 14.82 (1H, s, COOH); IR (KBr): cm
1 =
1584 (C‚C), 1718 (C‚O), 1260 (C–O), 1003 (C–N), 2916
(C–H), 3415 (COOH); MS: m/z= 538.6 (M+).
2.2.2.8. 1-Cyclopropyl-6-ﬂuoro-7-(4-(N-(6-methyl-1,3-ben-
zothiazol-2-yl)amino methyl)piperazin-1-yl)-1,4-dihydro-4-oxo-
quinoline-3-carboxylic acid (4h). Mp 302–305 C (71% yield).
1H NMR (DMSO-d6): d/ppm = 1.17 (4H, J= 5.4, d, CH2–
CH2– cyclopropyl), 3.06–3.14 (1H, m, CH cyclopropyl),
3.36–3.81 (8H, m, piperazine), 1.90 (3H, s, CH3 benzothia-
zole), 5.74 (2H, s, CH2 methylene bridge), 5.13 (1H, s, NH),
6.98–7.57 {5H, m, aromatic proton (H5, H8-quinolone and
H40, H50, H70-benzothiazole)}, 8.69 (1H, s, H2-quinolone),
15.00 (1H, s, COOH); IR (KBr): cm1 = 1585 (C‚C), 1710
(C‚O), 1250 (C–O), 1095 (C–N), 2916 (C–H), 3279 (COOH).
2.2.2.9. 1-Cyclopropyl-6-ﬂuoro-7-(4-(N-(6-ﬂuoro-1,3-ben-
zothiazol-2-yl)amino methyl)piperazin-1-yl)-1,4-dihydro-4-
oxo-quinoline-3-carboxylic acid (4i). Mp 275–278 C (66%
yield). 1H NMR (DMSO-d6): d/ppm = 1.13 (4H, J= 6.6, d,
CH2–CH2– cyclopropyl), 3.09–3.18 (1H, m, CH cyclopropyl),
3.29–3.77 (8H, m, piperazine), 5.73 (2H, s, CH2 methylene
bridge), 5.12 (1H, s, NH), 6.97–7.76 {5H, m, aromatic proton
(H5, H8-quinolone and H40, H50, H70-benzothiazole)}, 8.65 (1H,
s, H2-quinolone), 14.86 (1H, s, COOH); IR (KBr): cm
1 =
1583 (C‚C), 1710 (C‚O), 1211 (C–O), 1041 (C–N), 3070–
2831 (C–H), 3410 (COOH).
674 P.C. Sharma et al.2.2.2.10. 7-(4-(N-(6-bromo-1,3-benzothiazol-2-yl)aminomethyl)
piperazin-1-yl)-1-cyclopropyl-6-ﬂuoro-1,4-dihydro-4-oxo-quin-
oline-3-carboxylic acid (4j). Mp 257-260 C (65% yield). 1H
NMR (DMSO-d6): d/ppm = 1.18 (4H, J= 7.5, d, CH2–
CH2– cyclopropyl), 3.08–3.18 (1H, m, CH cyclopropyl),
3.30–3.73 (8H, m, piperazine), 5.76 (2H, s, CH2 methylene
bridge), 5.01 (1H, s, NH), 7.02–7.98 {5H, m, aromatic proton
(H5, H8-quinolone and H40, H50, H70-benzothiazole)}, 8.65 (1H,
s, H2-quinolone), 15.19 (1H, s, COOH); IR (KBr):
cm1 = 1586 (C‚C), 1709 (C‚O), 1258 (C–O), 1052 (C–
N), 2932 (C–H), 3415 (COOH).2.2.2.11. 1-Cyclopropyl-6-ﬂuoro-8-methoxy-7-(3-methyl-4-(N-
(6-nitro-1,3-benzothiazol-2-yl)aminomethyl)piperazin-1-yl)-
1,4-dihydro-4-oxo-quinoline-3-carboxylic acid (4k). Mp 226–
229 C (66% yield). 1H NMR (DMSO-d6): d/ppm = 0.94
(4H, J= 7.2, d, CH2–CH2– cyclopropyl), 2.96–3.06 (1H, m,
CH cyclopropyl), 3.29–3.65 (7H, m, piperazine), 2.47 (3H, s,
CH3 piperazine), 3.92 (3H, s, OCH3), 5.73 (2H, s, CH2 meth-
ylene bridge), 5.12 (1H, s, NH), 7.14–7.93 {4H, m, aromatic
proton (H5-quinolone and H40, H50, H70-benzothiazole)}, 8.76
(1H, s, H2-quinolone), 14.86 (1H, s, COOH); IR (KBr):
cm1 = 1583 (C‚C), 1710 (C‚O), 1250 (C–O), 1196 (C–
N), 3086 (C–H), 3387 (COOH); MS: m/z= 582.6 (M+).2.2.2.12. 1-Cyclopropyl-6-ﬂuoro-7-(4-(N-(6-ﬂuoro-1,3-ben-
zothiazol-2-yl)aminomethyl)-3-methylpiperazin-1-yl)-8-meth-
oxy-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid (4l). Mp
182–184 C (61% yield). 1H NMR (DMSO-d6): d/ppm =
1.21 (4H, J= 7.8, d, CH2–CH2– cyclopropyl), 3.01–3.12
(1H, m, CH cyclopropyl), 3.26–3.72 (7H, m, piperazine),
2.39 (3H, s, CH3 piperazine), 3.89 (3H, s, OCH3), 5.73 (2H,
s, CH2 methylene bridge), 5.13 (1H, s, NH), 6.99–7.83 {4H,
m, aromatic proton (H5-quinolone and H40, H50, H70-benzothi-
azole)}, 8.69 (1H, s, H2-quinolone), 15.13 (1H, s, COOH); IR
(KBr): cm1 = 1583 (C‚C), 1712 (C‚O), 1250 (C–O), 1196
(C–N), 3086 (C–H), 3279 (COOH).2.3. Biological evaluation
2.3.1. Antibacterial activity assay
The newly synthesized compounds (4a–l) were evaluated for
antibacterial activities using agar well diffusion method and
by minimum inhibitory concentration (MIC) method Kumar
et al., 2009; McFarland, 1907. Nutrient agar media and King’s
B media were used for the biological assay as per the following
composition: Nutrient agar media (NAM) made up of peptone
5 g, beef extract 3 g, NaCl 5 g, nutrient agar 2% and the ﬁnal
volume of media was adjusted to 1000 ml with double distilled
water (pH 7.0). King’s B media containing peptone 2%, glyc-
erol 1%, KH2PO4 0.15%, MgSO4 0.15%, agar 2% and the ﬁ-
nal volume of media was adjusted to 1000 ml with distilled
water (pH 7.0). Synthesized compounds were screened for anti-
bacterial activities against two Gram-positive bacteria, that is,
Staphylococcus auerus (NCDC 110), Bacillus subtilis (NCDC
71) and two Gram-negative bacteria, that is, Escherichia coli
(NCDC 134), Pseudomonas aeruginosa (NCDC 105). The bac-
terial cultures were revived as per the protocol provided by
National Collection of Dairy Cultures (NCDC), Karnal, In-
dia. P. aeruginosa culture was maintained on King’s B mediawhile all other cultures were maintained on nutrient agar med-
ia. Suspension of each test organism was prepared to evaluate
antibacterial activity of the synthetic compounds. All stock
cultures were stored at 4 C.
Each petri plate was prepared by pouring 40 ml of appro-
priate agar media. A ﬁxed volume (100 ll) of respective micro-
organism was spread on each petri plate with the help of a
spreader. In each seeded agar plate, wells were bored using a
borer of 6 mm diameter. Three concentrations (100, 50,
10 lg/ml) of each compound reconstituted in dimethyl sulph-
oxide (DMSO) were added to the wells of seeded plates.
DMSO was used as a control for all the experiments. The
plates were kept in laminar air ﬂow for 15 min to allow diffu-
sion of the compounds into agar. The plates were incubated at
37 C for 16 h and antibacterial activity was determined by
measuring the diameter of inhibition zone. Each test was per-
formed in triplicates and mean diameter of zone of inhibition
was calculated. The results obtained were compared against
three standard drugs, that is, ciproﬂoxacin, norﬂoxacin,
gatiﬂoxacin.
MIC of the synthesized compounds was determined using
the method described by Kumar et al. (2009). A stock solution
of 3 mg/ml of each compound was prepared in DMSO and
further diluted to get a ﬁnal concentration ranging from
200–0.05 lg/ml. Optical density was measured at 600 nm using
UV-visible spectrophotometer. The minimum concentration,
where no microbial growth was observed is called as MIC of
the compound.
3. Results and discussion
Our synthetic route to target compounds is presented in
Scheme 1. The requisite 2-amino-6-substituted benzothiazoles
(2a–e) were prepared according to the method described by
Stuckwisch (Stuckwisch, 1949). Reaction of ﬂuoroquinolones,
benzothiazole and formalin in the presence of glacial acetic
acid afforded target compounds.
The newly synthesized compounds are characterized by
spectral analysis (IR, 1H NMR and mass). The 1H NMR
spectra showed characteristic peak in DMSO-d6 at 5.3–5.7 d
(singlet 2H) –CH2 methylene bridge, 4.8–5.2 d (singlet 1H) of
-NH, 8.6–8.9 d (singlet 1H) of H2 quinolone and 14.7–15.3 d
(broad singlet 1H) of –COOH group. Characteristic peaks in
IR spectra were obtained at (KBr) v cm1 at approximately
1710, 1300, 3400, 2900, 3000 and 1600.
All the synthesized ﬂuoroquinolone derivatives were
screened for antibacterial activities against two Gram positive
bacterial strains, that is, S. auerus (NCDC 110), B. subtilis
(NCDC 71) and two Gram negative strains, that is, E. coli
(NCDC 134), P. aeruginosa (NCDC 105). The antibacterial
activity was determined by measuring the diameter of zone
of inhibition and minimum inhibitory concentration (MIC).
The results of zone of inhibition and MIC screening are sum-
marized in Tables 1 and 2 respectively.
These novel derivatives demonstrated varying antibacterial
activities (zone of inhibition) against different strains.
Compound 1-cyclopropyl-6-ﬂuoro-7-(4-(N-(6-ﬂuoro-1,3-ben-
zothiazol-2-yl)amino methyl)piperazin-1-yl)-1,4-dihydro-4-oxo-
quinoline-3-carboxylic acid (4i), possessing ﬂuoro functionality
at 6-position of benzothiazole nucleus depicted the signiﬁcant
zone of inhibition of 9.8, 10.0 and 15.3 mm at 10, 50 and
Scheme 1 Synthetic route of target compounds.
Synthesis and antibacterial evaluation of novel analogs 675100 lg/ml concentrations, respectively, against S. auerus.
Compounds 4g and 4k both have the nitro functional group at
6-position of benzothiazole moiety, also showed signiﬁcantly
potent antibacterial activities against S. auerus. However,
compound 1-cyclopropyl-6-ﬂuoro-7-(4-(N-(6-methyl-1,3-ben-
zothiazol-2-yl)amino methyl)piperazin-1-yl)-1,4-dihydro-4-oxo-
quinoline-3-carboxylic acid (4h) showed moderate activity.
6-Fluoro substituted benzothiazole containing derivatives of
ciproﬂoxacin (4i) and gatiﬂoxacin (4l) showed zone of inhibition
of 4.5 mm at concentration 10 lg/ml against B. subtilis. Com-
pounds 4f, 4h, 4j and 4k showed good antibacterial activities
against B. subtilis. Analog 1-cyclopropyl-6-ﬂuoro-7-(4-(N-(6-
ﬂuoro-1,3-benzothiazol-2-yl)aminomethyl)piperazin-1-yl)-1,4-di-
hydro-4-oxo-quinoline-3-carboxylic acid (4i) and 1-cyclopropyl-6-ﬂuoro-7-(4-(N-(6-ﬂuoro-1,3-benzothiazol-2-yl)aminomethyl)-
3-methylpiperazin-1-yl)-8-methoxy-1,4-dihydro-4-oxo-quino-
line-3-carboxylic acid (4l) were found to possess even better
antibacterial activities than the standard antibiotics norﬂoxacin
and gatiﬂoxacin when tested against E. coli and 4f showed
comparable activities at higher concentration (50 lg/ml and
100 lg/ml). Compounds 4d and 4g depicted superior antibacte-
rial activities as compared to the standard antibiotic norﬂoxacin
when tested against P. aeruginosa.
When tested against S. auerus ciproﬂoxacin annulated
with 6-methoxy benzothiazole (4f) derivative showed MIC
of 08 lg/ml, which reveals that it is approximately eight
times more potent as compared to standard drug ciproﬂox-
acin (MIC value 50 lg/ml). While some norﬂoxacin (4a, 4c
Table 1 Zone of inhibition in mm at 10, 50 and 100 lg/ml concentrations.
Product S. auerus (NCDC 110) B. subtilis (NCDC 71) E. coli (NCDC 134) P. aeruginosa (NCDC 105)
10 50 100 10 50 100 10 50 100 10 50 100
4a –– 3.5 6.8 –– 3.5 5.0 –– 3.0 4.8 –– 3.3 4.4
4b –– –– –– –– –– –– –– 3.8 3.8 –– –– ––
4c –– 4 5 1.0 1.5 2.0 –– 4.8 5.8 –– –– ––
4d –– –– 4 –– –– –– –– 2.0 2.8 3.3 3.8 4.8
4e –– –– –– –– –– 4.5 –– 2.8 3.8 –– –– 4.5
4f 2.3 7.5 8.8 3.0 6.0 6.5 3.3 7.8 10.0 –– 5.3 8.0
4g 4.5 8.8 9.3 –– 4.8 5.4 4.3 8.0 8.5 3.5 5.5 6.3
4h 5.0 8.8 11.5 3.5 7.5 8.0 4.3 7.5 7.5 –– 3.0 7.3
4i 9.8 10.0 15.3 4.5 6.5 8.3 6.8 9.5 13.8 –– 3.5 8.5
4j 2.0 6.3 9.0 3.2 5.5 8.0 4.0 7.0 9.0 –– –– ––
4k 6.8 9.0 11.0 3.8 7.5 8.8 3.8 8.0 10.0 –– –– 3.0
4l –– 7.5 10.5 4.5 8.0 9.0 6.5 10.0 11.5 –– –– ––
Norﬂoxacin 9.2 10.5 12.5 5.0 8.0 10.2 4.2 8.5 10.8 1.0 2.0 7.2
Ciproﬂoxacin 8.0 11.0 13.0 8.0 11.0 12.2 8.2 10.5 11.3 4.5 8.0 10.9
Gatiﬂoxacin 8.0 11.0 11.3 6.5 10.2 11.5 6.0 9.7 9.8 2.7 4.2 4.7
Control –– –– –– –– –– –– –– –– –– –– –– ––
Table 2 Minimum inhibitory concentration (MIC) in lg/ml against S. auerus, B. subtilis, E. coli, P. aeruginosa bacterial strains.
Product S. auerus (NCDC 110) B. subtilis (NCDC 71) E. coli (NCDC 134) P. aeruginosa (NCDC 105)
4a 25 50 30 30
4b 110 50 50 130
4c 20 90 05 80
4d 100 170 110 130
4e 10 110 01 20
4f 08 70 25 50
4g 150 80 100 20
4h 70 25 60 50
4i 80 130 50 50
4j 15 100 05 175
4k 50 50 30 35
4l 10 110 30 50
Norﬂoxacin 10 05 70 15
Ciproﬂoxacin 50 20 25 60
Gatiﬂoxacin 05 100 100 50
Control –– –– –– ––
676 P.C. Sharma et al.and 4e) and gatiﬂoxacin derivatives (4k and 4l) showed a
comparable activity. Compounds 4a, 4b, 4h and 4k showed
signiﬁcant MICs against B. subtilis when compared with
standards. Moreover, compound 4h possessing methyl group
at 6-position of benzothiazole part of novel derivative
showed better MIC (25 lg/ml) against B. subtilis than stan-
dard antibiotic gatiﬂoxacin (MIC value 100 lg/ml). Deriva-
tive 4e bearing bromo substitution at 6-position of
benzothiazole nucleus, exhibited 25 times more potent activ-
ity with MIC value 01 lg/ml against strain E. coli, when
compared to the standard drug ciproﬂoxacin (MIC value
25 lg/ml) and was 70 times more potent than standard drug
norﬂoxacin (MIC value 70 lg/ml). Interestingly the same
compound exhibited 100 times more potent MIC than stan-
dard drug gatiﬂoxacin having MIC 100 lg/ml when tested
against E. coli. Analog 4c, 4e, 4f and 4j showed superior
MIC than the standard antibiotics ciproﬂoxacin, norﬂoxacin
and gatiﬂoxacin when tested against E. coli. Most of the allcompounds showed comparable MIC against the standard
antibiotics norﬂoxacin and gatiﬂoxacin when tested against
P. aeruginosa.4. Conclusion
In conclusion, we have synthesised twelve novel derivatives of
three ﬂuoroquinolone drugs, that is, norﬂoxacin, ciproﬂoxacin
and gatiﬂoxacin. Fluoroquinolone drugs norﬂoxacin,
ciproﬂoxacin and gatiﬂoxacin have been linked to different
2-amino-6-substituted benzothiazoles via methylene bridge
linkage. The derivatives are characterized by physicochemical
and spectral analysis such as IR, 1H NMR and mass. The spec-
tral data obtained was in full agreement with proposed struc-
tures. The in vitro evaluation of newly synthesized
compounds revealed improved therapeutic effectiveness as
compared to the parent drugs. Some derivatives showed more
Synthesis and antibacterial evaluation of novel analogs 677potent or equipotent antibacterial activities against the selected
strains. Experimental data of the present studies reveal that the
synthesized novel derivatives of ﬂuoroquinolones have
remarkable antibacterial potential.
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